Kaneda et al.180 found in preclinical studies that a PI3K-γ inhibitor could induce a shift in TAMs from M2 to M1 phenotype, restored CD8 + T cell activation and cytotoxicity, thereby inhibiting the growth of checkpoint inhibitor-resistant tumor. This evidence concerns the gene CD8A and neoplasm.